NeuroRx, a platform biotech company focused on breakthrough treatments for suicidal depression and PTSD, now entering phase 3 studies under leadership of Harvard/Mass General Hospital.
More: Full Company Brief and Event Page
Who should attend: Single Family Office investors and HNW investors, and strategic investors.
What: Opportunity to participate in preferred stock financing. More than $11 million has already been funded in this round, including lead head fund investor, C-Health led by the former President of Teva, and other family offices and HNW individuals. NeuroRx was recognized as startup of the year by the Israeli Biotechnology Association and Israel’s Office of the Chief Scientist.
This privately held clinical stage pharmaceutical company has pioneers a patented approach simultaneously targeting two brain receptors (NMDA and D2/5HT2A) in order to develop the first oral drug that has shown sustained reduction in suicidal ideation and has shown a preclinical efficacy signal for treatment of PTSD. Depression affects more than 330 million people worldwide and, according to the World Health Organization, more than 1 million commit suicide annually. Current, SSRI antidepressants are ineffective in 50% of people and are associated with an increased risk of suicide. NeuroRx’s first candidate drug, NRX-101 has been shown in human phase 2 studies to decrease suicidal ideation by more than 75%. The FDA has determined that NRX-101 meets the criteria for Breakthrough Designation and has granted an IND for the drug to proceed to phase 2/3 clinical trials.
When: Tuesday, June 6, 2017, 12:00 PM to 2:00 PM
Where: Kirkland and Ellis, LLP, 601 Lexington Avenue, New York, NY 10022
Family Office Insights Peer Insights Report Q&A – Jonathan Javitt
Chairman, CEO and Co-Founder of NeuroRx, Inc.
Company Overview:
CNS PLATFORM COMPANY FOCUSED ON
TREATMENTS FOR SUICIDAL IDEATION AND PTSD
- Addressing multi-billion dollar unmet needs in suicidal depression and PTSD.
- Mid/late stage programs include Phase II/III Bipolar Depression and Phase II PTSD.
- First-in-class and likely first to market in suicidal bipolar depression.
- Unique, patent-issued, dual-action combination therapy.
- Well-established, benign safety profile and approved IND provide substantially de-risked path to commercialization.
- Extensive, global IP portfolio provides significant protection, covering composition of matter, formulation, combination therapy, route and method of administration.
- Management team with demonstrated track record of successful commercial drug development.
THE COMPANY: NeuroRx, Inc. is a privately held clinical stage pharmaceutical company developing next generation therapies to treat suicidal depression. Built around patented technology developed by Prof. Daniel Javitt, MD, PhD, of Columbia University, initial product candidate (NRX-101) is a novel dual-targeted small-molecule drug that has been shown to reduce symptoms of suicidal ideation by more than 75%, never before shown for an oral medication. Moreover, the drug was seen to reduce overall symptoms of depression by more than 50%, comparable to market-leading antidepressants. Until now, the only approved treatment shown to directly reduce suicidal ideation has Electroconvulsive Therapy (ECT), despite its many undesirable side effects. Newly-published research from Columbia University demonstrates that NRX-101 achieves beneficial changes in brain chemistry that equal or exceed those shown with ECT, with no evidence to ECT side effects. Those same human biomarker studies, together with additional pre-clinical studies demonstrate that NRX-101 also addresses the brain chemistry deficit associated with Post-traumatic Stress Disorder. NRX-101 is the only oral therapy currently in FDA phase 2/3 trials for acute suicidal ideation and behavior, a life-threatening unmet medical need and is now entering phase 2 trials for treatment of PTSD. We expect to complete these studies in the second half of 2018.
RSVP deadline is past